Loading…
Coloplast signed an agreement to acquire Kerecis, a company in the biologics wound care segment, for up to USD 1.3 billion, with an upfront cash payment of USD 1.2 billion. Kerecis develops wound care products based on fish skin.
Coloplast signed an agreement to acquire Kerecis, a biologics wound care company, for up to USD 1.3 billion, with an upfront cash payment of USD 1.2 billion. Kerecis is based in Ísafjörður, Iceland, and uses fish skin technology for wound healing.